• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Inflammatory Bowel Disease Therapeutics - Global Strategic Business Report Product Image

Inflammatory Bowel Disease Therapeutics - Global Strategic Business Report

  • ID: 1227788
  • April 2010
  • Region: Global
  • 611 Pages
  • Global Industry Analysts, Inc

This report analyzes the Global market for Inflammatory Bowel Disease Therapeutics in US$ Million.

Annual estimates and forecasts are provided for the period 2006 through 2015.

The report profiles 69 companies including Abbott Laboratories, Biogen Idec, Inc., Cosmo Pharmaceuticals SpA, ChemoCentryx, Inc., Dr. Falk Pharma GmbH, Eisai Co., Ltd., Elan Corporation, plc, Ferring Pharmaceuticals A/S, GlaxoSmithKline plc, Johnson & Johnson, Centocor Ortho Biotech, Inc, Kyorin Pharmaceutical Co., Ltd., Merck Serono, Millennium Pharmaceuticals, Inc., Mitsubishi Tanabe Pharma Corporation, Novartis AG, Otsuka Pharmaceutical Co. Ltd., Prometheus Laboratories, Inc., Shire plc, UCB SA, and Wyeth.

Market data and analytics are derived from primary and secondary research.

Company profiles are mostly extracted from URL research and reported select online sources.

Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks.

For information on site licence pricing please click on Enquire before buying

Note: Product cover images may vary from those shown

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-2
Quantitative Techniques & Analytics I-3
Product Definitions and Scope of Study I-3

II. Executive Summary

1. INDUSTRY OVERVIEW II-1
Introduction II-1
Biological Drugs Lead the IBD Therapeutics Bandwagon II-1
Leading Biological Drugs Approved for Treatment of Crohn’s
Disease II-1
Year of Approval for Leading Drugs in Crohn’s Disease Treatment II-2
Impact of the Economic Recession on the Pharmaceutical Industry II-2
Recession Brings Drug Development Efforts Under Siege II-2
Biotech Bankruptcies Rife in the Current Economic Downturn II-3
Current and Future Analysis II-3
Table 1: World Recent Past, Current & Future Analysis for
Inflammatory Bowel Disease Therapeutics by Disease Type -
Crohn’s Disease and Ulcerative Colitis Markets Independently
Analyzed with Annual Sales in US$ Million for Years 2006
through 2015 (includes corresponding Graph/Chart) II-4

Table 2: World 9-Year Perspective for Inflammatory Bowel
Disease Therapeutics by Disease Type - Percentage Breakdown
of Dollar Sales for Crohn’s Disease and Ulcerative Colitis
Markets for the Years 2006, 2009 & 2015 II-4
Regional Market Overview II-4
United States II-4
Lialda’s Share Gaining Momentum in Ulcerative Colitis Drugs
Market II-5
Key Ulcerative Colitis Drugs in the US (2006) II-5
Table 3: US Ulcerative Colitis Drugs Market (2007 & 2008):
Percentage Breakdown of Prescriptions Dispensed Ranked by
Leading Drugs for Asacol, Pentasa, Lialda, Canasa,
Sulphasalazine, Colazal, Other Drugs and Generics (includes
corresponding Graph/Chart) II-6
Canada II-6
Key Challenges Lie ahead II-6
Productivity Loss to the Nation II-7
Australia II-7
Japan II-7
Europe II-8
Increasing Awareness to Drive Market Growth II-8
United Kingdom II-8

2. IBD - AN OVERVIEW II-9
Prevalence and Incidence II-9
Women More Susceptible to IBD II-9
Etiology of Inflammatory Bowel Disease II-10
Genetic Predisposition II-10
Environmental Factors II-11
IBD - A Health and Social Burden II-11
Inflammatory Bowel Disease Types II-11
Crohns Disease (CD) II-11
Ulcerative Colitis (UC) II-12
Clinical Manifestations II-12
Signs and Symptoms II-12
Diagnosis II-13
Pathogenesis II-14
Outcomes II-14
Treatment Strategies II-15
Step I (Aminosalicylates) II-15
5-aminosalicylic acid (5-ASA) Derivatives and Available
Brands in the US Market II-15
Step II (Antibiotics) II-16
Step III (Corticosteroids) II-16
Available Corticosteroidal Drugs As per Mode of Administration II-16
Step IV (Immuno-modifying Agents) II-17
Overview of Select Biological Drugs II-17
Infliximab (Remicade) II-17
Adalimumab (Humira) II-18
Certolizumab pegol (Cimzia) II-18
Natalizumab (Tysabri) II-18
Step V (Experimental Medication) II-18
Experimental Medication Drugs for IBD with Dosage Settings II-19
Ileal Pouch recommended in Conditions of Ulcerative Colitis II-19
Comparing Crohn’s Disease and Ulcerative Colitis II-19
Comparison of Characteristics of Ulcerative Colitis and
Crohn’s Disease II-20

3. PRODUCT INNOVATIONS/LAUNCHES II-21
Procter & Gamble Pharmaceuticals Introduces Asacol HD II-21
Exagen Diagnostics Introduces eXaIBS Test and eXaIBD Test II-21
Cimzia® Receives FDA Nod for Treating Crohn’s Disease II-21
Kyorin Pharmaceutical Launches Pentasa Tablets 500 II-21
Xian-Janssen Introduces Remicade, Branded infliximab in China II-22
HUMIRA® Obtains EU Approval for Treating Crohn’s Disease II-22
Salix and Watson to Launch COLAZAL® Authorized Generic II-22

4. RECENT INDUSTRY ACTIVITY II-23
GlaxoSmithKline Enters into Partnerships with Biotica,
Dynavax, and Archemix II-23
Sequenom Buys AttoSense Portfolio and Other Assets from SensiGen II-23
Zeria Pharmaceutical to Take Over Tillotts Pharma II-24
Meridian Bioscience Europe Signs Agreement with BUHLMANN
Laboratories II-24
Sosei Group Inks Deal with Biocopea II-24
UCB Receives FDA Approval for Cimzia II-24
Regeneron Pharmaceuticals and Sanofi-aventis Extend Global
Collaboration II-25
Celldex Therapeutics Acquires CuraGen II-25
Onyx Pharmaceuticals Acquires Proteolix II-25
Roche Acquires ARIUS Research, Inc. II-26
Nycomed Inks Agreement with Immunomedics for Veltuzumab II-26
Archemix Inks Deal with GlaxoSmithKline II-27
Boehringer to Takeover Actimis II-27
J&J PRD Grants Milestone Payment to Sunesis Pharmaceuticals II-28
The Asian Institute of Gastroenterology Establishes New facility II-28
TPG Capital Acquires Axcan Pharma II-28
Cosmo Pharmaceuticals Collaborates with Santarus II-28
BioLineRx Inks License Agreement with Yissum II-29
Salix Pharmaceuticals Secures FDA Approval for APRISO™ II-29
Omeros Inks Agreement with Affitech II-29
GlaxoSmithKline Enters into Strategic Alliance with Regulus
Therapeutics II-29
Roche to Take Over Piramed II-30
Evotec Acquires Renovis II-30
Takeda Pharmaceutical Acquires Millennium Pharmaceuticals II-30
GlaxoSmithKline Takes Over Sirtris Pharmaceuticals II-31
Boehringer Ingelheim Inks Agreement with Actimis Pharmaceuticals II-31
GlaxoSmithKline Enters into a Strategic Alliance with Archemix II-31
Pipex Pharmaceuticals Buys Oral dnaJP1 II-31
Emergent BioSolutions Acquires AVANIR’s Anthrax Monoclonal
Antibody Collection II-32
Ferring Inks License Agreement with Conaris II-32
ZymoGenetics and Merck Serono Restructure Their Partnership II-32
Evotec Acquires Renovis II-32
ViroPharma Acquires Lev Pharmaceuticals II-33
TPG Capital Inks Agreement to Acquire Axcan Pharma II-33
Meyer Pharmaceuticals Inks Agreement with AnGes II-33
The School of Pharmacy Enters Into Collaboration with Tillotts
Pharma II-33
Sequenom Inks Collaborative Agreement with SensiGen II-34
Evotec Signs Collaborative Agreement with Interprotein II-34
Shire Obtains Approval from FDA for LIALDA™ (mesalamine) II-34
Amgen Acquires Avidia II-35
Pipex Pharmaceuticals Acquires Remaining Stake in Effective
Pharmaceuticals II-35

5. FOCUS ON SELECT GLOBAL PLAYERS II-36
Abbott Laboratories (US) II-36
Biogen Idec, Inc. (US) II-36
Cosmo Pharmaceuticals SpA (Italy) II-37
ChemoCentryx, Inc. (US) II-37
Dr. Falk Pharma GmbH (Germany) II-37
Eisai Co., Ltd. (Japan) II-38
Elan Corporation, plc (Ireland) II-38
Ferring Pharmaceuticals A/S (Denmark) II-39
GlaxoSmithKline plc (UK) II-39
Johnson & Johnson (US) II-40
Centocor Ortho Biotech, Inc. (US) II-40
Kyorin Pharmaceutical Co., Ltd. (Japan) II-40
Merck Serono (Switzerland) II-41
Millennium Pharmaceuticals, Inc. (US) II-41
Mitsubishi Tanabe Pharma Corporation (Japan) II-41
Novartis AG (Switzerland) II-42
Otsuka Pharmaceutical Co. Ltd. (Japan) II-42
Prometheus Laboratories, Inc. (US) II-43
Shire Plc (UK) II-43
UCB SA (Belgium) II-43
Wyeth (US) II-44

III. COMPETITIVE LANDSCAPE

Total Companies Profiled: 69 (including Divisions/Subsidiaries - 77)

Region/Country Players

- The United States 39
- Canada 2
- Japan 8
- Europe 25
- France 1
- Germany 5
- The United Kingdom 6
- Italy 2
- Spain 1
- Rest of Europe 10
- Asia-Pacific (Excluding Japan) 1
- Middle East 2

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos